SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41st Annual National Society of Genetic Counselors (NSGC) meeting, Nov. 16-19 in Nashville, Tenn.
“In today’s patient-centric healthcare system, genetic counselors play an integral role by empowering patients and physicians with data-driven genetic insights and personalized medical information to support critical healthcare decisions,” said Paul J. Diaz, president and CEO, Myriad Genetics. “We’re committed to increasing collaboration with the genetic counselor community to make genetic testing more accessible, affordable and easier to use for all patient populations.”
On Saturday, Nov. 19 at 12:30 p.m. CT, Myriad will host a CEU symposium titled ‘How inclusion, accessibility, innovation and collaboration are shaping the future of precision medicine’, presented by Nicole Lambert, chief operating officer; Thomas Slavin, M.D., chief medical officer; Dale Muzzey, Ph.D., chief scientific officer; and Susan Manley, senior vice president of Medical Services. Myriad also will share a poster titled ‘Curation of pathogenic genome-wide copy number variants in a noninvasive prenatal screen (NIPS)’ by Sam Cox, Ph.D., senior clinical genomics scientist. Data will highlight how technological improvements now allow for the detection of copy number variants (CNVs) across the genome in NIPS.
Among the Myriad products highlighted in the company’s NSGC exhibit (#307) are:
Myriad Live from NSGC
Myriad will conduct a series of livestreams from NSGC available on the company’s social channels – Facebook, LinkedIn and Twitter – including the following:
Special events for genetic counselors
Myriad Genetics will sponsor NSGC’s welcome reception for all genetic counselors who are first-time conference attendees, Wednesday, Nov. 16, 6:00-7:00 p.m. CT. Myriad also will host its 9th Annual Genetic Counselor Appreciation Event and fundraiser on Friday, Nov. 18, 7:30-11:30 p.m. CT, supporting Touch4Life; Eva’s Butterfly Wishes/National Organization for Rare Disorders; and CONNECTUS Health.
1 Hughes et al. JCO Precision Oncology 2022 (https://ascopubs.org/doi/abs/10.1200/PO.22.00084)
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s commitment to increase collaboration with the genetic counselor community to make genetic testing more accessible, affordable and easier to use for all patient populations. These “forward-looking statements” are based on management’s expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact: Megan Manzari (385) 318-3718 Megan.Manzari@myriad.com |
Investor Contact: Matt Scalo (801) 584-3532 Matt.Scalo@myriad.com |
NEWTOWN, Pa., Dec. 22, 2024 /PRNewswire/ -- The law firm of Edelson Lechtzin LLP is…
Miami, Florida--(Newsfile Corp. - December 21, 2024) - Amid the vibrant backdrop of Art Basel…
Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…
MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…
Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…